What is CorMedix's EPS (diluted)?

CorMedix (CRMD) reported EPS (diluted) of $0.43 in Q1 2026.

How has CorMedix's EPS (diluted) changed year-over-year?

CorMedix's EPS (diluted) increased by 43.3% year-over-year, from $0.30 to $0.43.

What is the long-term trend for CorMedix's EPS (diluted)?

Over 3 years (2021 to 2025), CorMedix's EPS (diluted) has grown at a 36.6% compound annual growth rate (CAGR), from -$0.75 to $1.91.

What does EPS (diluted) mean?

Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

CorMedix CRMD EPS (Diluted)

Discontinued — last reported Q1 '26

EPS (Diluted) at other companies

PfizerPFE

$0.47-9.6%

Merck & Co.MRK

-$1.72-186%

Merit Medical SystemsMMSI

$0.68+38.8%

ITG

Integer HoldingsITGR

$0.48+173%

IAR

Integra LifeSciencesIART

-$0.06+81.8%

MiMedx GroupMDXG

-$0.07-240%

Other financials

Income statement

See full

Revenue$127.4M+226%

Gross profit$115.4M+207%

Operating income$63.7M+216%

Net income$38.6M+87.0%

Balance sheet

See full

Cash & equivalents$179.1M+170%

Total debt$4.3M+729%

Total equity$437.0M+280%

Total assets$815.6M+445%

Cash flow

See full

Operating cash flow$42.4M+115%

CapEx$729.0K+7,190%

Free cash flow$41.7M+111%

Valuation

See full

Market cap$605.65M-34.4%

P/E3.4×—

P/S1.5×-9.6×

Profitability

See full

Gross margin91.9%-3.5pp

Operating margin48.4%—

Net margin45.2%—

FCF margin48.7%+38.8pp

Returns & leverage

See full

Return on equity65.6%—

Debt / equity0×0.0×

Current ratio3×-1.2×

Where this comes from

Reported directly by CorMedix in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The official record: CorMedix’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about CorMedix's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is CorMedix's EPS (diluted)?: CorMedix (CRMD) reported EPS (diluted) of $0.43 in Q1 2026.
How has CorMedix's EPS (diluted) changed year-over-year?: CorMedix's EPS (diluted) increased by 43.3% year-over-year, from $0.30 to $0.43.
What is the long-term trend for CorMedix's EPS (diluted)?: Over 3 years (2021 to 2025), CorMedix's EPS (diluted) has grown at a 36.6% compound annual growth rate (CAGR), from -$0.75 to $1.91.
What does EPS (diluted) mean?: Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.